TCDAQ — Tricida Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
FDA's recent spate of 'surprising' rejections prompt concerns - Cowen
Tricida Inc: Falls after FDA declines to approve lead kidney disease drug
Brief: Tricida Receives Complete Response Letter From FDA For Veverimer To Treat Kidney Disease
Brief: Tricida Announces Second Quarter 2020 Financial Results
Brief: Tricida Provides Regulatory Update On Veverimer
Brief: Tricida Prices Offering Of $175 Million 3.50% Convertible Senior Notes Due 2027
U.S. STOCKS ON THE MOVE-Xenetic Biosciences, Dycom, Dynavax Technologies
U.S. STOCKS ON THE MOVE-KemPharm, Flotek, Arbutus Biopharama
Tricida falls as kidney disease specialist launches convertible debt deal
Brief: Tricida Reports Proposed Offering Of $175 Mln Convertible Senior Notes Due 2027
Brief: Tricida Announces First Quarter 2020 Financial Results
Brief: Tricida Committed To Seeking FDA Approval For Commercialization Of Veverimer As Treatment For Metabolic Acidosis
Brief: Tricida Hires Robert McKague As Executive Vice President, General Counsel & Chief Compliance Officer
Brief: Tricida Reports Q4 Loss Per Share $1.17
Brief: Tricida Reports Q3 Loss Per Share $0.89
Brief: Tricida Announces FDA Acceptance Of New Drug Application For Veverimer
Brief: Tricida Says Entered Into Manufacturing, Commercial Supply Agreement With Patheon Austria
Brief: Tricida Files For Potential Mixed Shelf Offering; Size Not Disclosed
Brief: Tricida Q2 Loss Per Share $0.75